Navigation Links
Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
Date:8/4/2009

LAUSANNE, Switzerland and WOBURN, Massachusetts, August 4 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Mercury Therapeutics, Inc. (Mercury), a privately held biotech company based in Woburn, Massachusetts focusing on the development of novel therapeutics for type 2 diabetes, cancer, and cardiovascular disease, announce the signature of an exclusive license agreement for the development and commercialisation of Debio 0930, a small molecule activator of AMPK (adenosine monophosphate activated protein kinase) for the treatment of diabetes and metabolic diseases. Activation of AMPK has been shown to lower fasting blood glucose levels and improve glucose disposal following a glucose challenge, two key goals in the management of type 2 diabetes.

Under the terms of the agreement, Debiopharm shall pay Mercury for continued research and development support, predefined advanced milestone payments during the development of the compound and a royalty based on net sales of commercialised product. First entry into man is expected for 2012.

"We are very enthusiastic about our collaboration with an experienced innovative biotech company like Mercury. Diabetes is a major cause of morbidity and mortality by disease globally and we are determined to improve the quality of patient's lives by developing a new therapy," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group."

"This alliance with Debiopharm represents important validation of Mercury's technology and of the growing appreciation of AMPK as a novel drug target for metabolic diseases. The development of an orally available direct activator of AMPK has the potential to be a first-in-class therapeutic for type 2 diabetes, hyperlipidemia, and a number of indications in oncology," added Dr. Neal Birnberg, CEO of Mercury, who was advised on this transaction by Katan Associates.

About Diabetes

Diabetes is a disease in which the body does not produce or properly use insulin. Insulin is a hormone that is needed to convert sugar, starches and other food into energy needed for daily life. The cause of diabetes continues to be a mystery, although both genetics and environmental factors such as obesity and lack of exercise appear to play roles.

Prevalence of diabetes worldwide is estimated at 180 million people, WHO predicts this number will rise to 366 million by 2030.

Type 2 diabetes (formerly called non-insulin-dependent or adult-onset) results from the body's ineffective use of insulin. Type 2 diabetes comprises 90% of people with diabetes around the world, and is largely the result of excess body weight and physical inactivity.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

About Mercury Therapeutics, Inc.

Located in Woburn, Massachusetts, Mercury Therapeutics is a privately held biotech company focusing on the development of AMPK activators as novel therapeutics for type 2 diabetes, cancer and cardiovascular disease. Mercury is focusing its internal AMPK drug development program for indications in oncology. Mercury's lead generation platform is based on a proprietary technology that enables the discovery and development of novel compounds that directly activate AMPK, a key regulator of whole body energy metabolism, cholesterol and fatty acid production, and cell division.

For more information on Mercury Therapeutics please visit: http://www.mtipharm.com.

    Debiopharm S.A. Contact:
    Maurice Wagner
    Director Corporate Affairs & Communication
    Tel: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69
    mwagner@debiopharm.com

    Additional Media Contacts:

    In London
    Maitland
    Brian Hudspith
    Tel: +44(0)20-7379-5151
    bhudspith@maitland.co.uk

    In New York
    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    Tel: +1-212-845-4292
    Fax: +1-212-845-4260
    martina.schwarzkopf@russopartnersllc.com

    Mercury Therapeutics Contact:
    Neal Birnberg, CEO
    Tel: +1-781-932-1125
    Fax: +1-781-347-4737
    birnberg@mtipharm.com


'/>"/>
SOURCE The Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
2. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
3. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
4. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
5. Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
6. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
7. Commonwealth Fund Case Study Points to Continuous Innovation at Group Health Cooperative
8. Top Medical Research Centers Form Velos Advisory Group for Service-Oriented Architecture
9. New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns
10. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
11. The Villa Group Informs on Mexico Travel Plans in Wake of Swine Flu Outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
Breaking Medicine News(10 mins):